[Monitoring of metastatic renal cell carcinoma--standards and challenges]

Area of Science:

• Oncology
• Radiology
• Pharmacology

Background:

• Targeted therapies have revolutionized metastatic renal cell carcinoma (mRCC) treatment, leading to increased patient life expectancy.
• This necessitates new approaches for monitoring tumor progression and managing treatment efficacy.
• Understanding the distinct mechanisms of targeted therapies compared to traditional cytotoxic drugs is essential.

Purpose of the Study:

• To outline updated recommendations for monitoring mRCC patients undergoing targeted therapy.
• To emphasize the critical role of imaging in assessing treatment response and guiding therapeutic decisions.
• To ensure optimal treatment duration and outcomes in the era of novel therapeutic agents.

Main Methods:

• Adherence to RECIST (Response Evaluation Criteria In Solid Tumors) criteria for standardized tumor assessment.
• Implementing imaging studies 6-9 weeks after therapy initiation to evaluate efficacy.
• Repeating follow-up examinations with identical imaging modalities every 2-3 months.
• Aligning imaging schedules with the treatment cycles of specific drugs, like Sunitinib, for consistent evaluation.

Main Results:

• Targeted therapies have extended survival, creating a need for refined monitoring protocols.
• Consistent and timely imaging is vital for assessing treatment effectiveness and detecting progression.
• Structured follow-up schedules, adapted to drug administration, are recommended for optimal management.

Conclusions:

• Effective monitoring of mRCC under targeted therapy requires precise imaging timing and interpretation.
• Following established guidelines like RECIST and adapting to drug cycles ensures maximal therapeutic benefit.
• This strategic approach to imaging assessment is key to improving long-term outcomes for mRCC patients.